"Pregnant women in any trimester should consider postponing travel to 14 countries and territories in South and Central America and the Caribbean where mosquitos are spreading the Zika virus, the Centers for Disease Control and Prevention (CDC) an"...
Quinupristin and dalfopristin are the main active components circulating in plasma in human subjects. Quinupristin and dalfopristin are converted to several active major metabolites: two conjugated metabolites for quinupristin (one with glutathione and one with cysteine) and one non-conjugated metabolite for dalfopristin (formed by drug hydrolysis).
Pharmacokinetic profiles of quinupristin and dalfopristin in combination with their metabolites were determined using a bioassay following multiple 60-minute infusions of Synercid in two groups of healthy young adult male volunteers. Each group received 7.5 mg/kg of Synercid intravenously q12h or q8h for a total of 9 or 10 doses, respectively. The pharmacokinetic parameters were proportional with q12h and q8h dosing; those of the q8h regimen are shown in the following table:
Mean Steady-State Pharmacokinetic Parameters of
Quinupristin and Dalfopristin in Combination with their Metabolites (± SD1)
(dose = 7.5 mg/kg q8h; n=10)
|Cmax2 (μg/mL)||AUC3 (μg•h/mL)||t ½4 (hr)|
|Quinupristin and metabolites||3.20 ± 0.67||7.20 ± 1.24||3.07 ± 0.51|
|Dalfopristin and metabolite||7.96 ± 1.30||10.57 ± 2.24||1.04 ± 0.20|
|1 SD= Standard Deviation
2 Cmax = Maximum drug plasma concentration
3 AUC = Area under the drug plasma concentration-time curve
4 t ½ = Half-life
The clearances of unchanged quinupristin and dalfopristin are similar (0.72 L/h/kg), and the steady-state volume of distribution for quinupristin is 0.45 L/kg and for dalfopristin is 0.24 L/kg.
The elimination half-life of quinupristin and dalfopristin is approximately 0.85 and 0.70 hours, respectively.
The total protein binding of quinupristin is higher than that of dalfopristin. Synercid does not alter the in vitro binding of warfarin to proteins in human serum.
Penetration of unchanged quinupristin and dalfopristin in noninflammatory blister fluid corresponds to about 19% and 11% of that estimated in plasma, respectively. The penetration into blister fluid of quinupristin and dalfopristin in combination with their major metabolites was in total approximately 40% compared to that in plasma.
In vitro, the transformation of the parent drugs into their major active metabolites occurs by nonenzymatic reactions and is not dependent on cytochrome-P450 or glutathione-transferase enzyme activities.
Synercid has been shown to be a major inhibitor (in vitro inhibits 70% cyclosporin A biotransformation at 10 μg/mL of Synercid) of the activity of cytochrome P450 3A4 isoenzyme. (See WARNINGS.)
Synercid can interfere with the metabolism of other drug products that are associated with QTc prolongation. However, electrophysiologic studies confirm that Synercid does not itself induce QTc prolongation. (See WARNINGS.)
Fecal excretion constitutes the main elimination route for both parent drugs and their metabolites (75 to 77% of dose). Urinary excretion accounts for approximately 15% of the quinupristin and 19% of the dalfopristin dose. Preclinical data in rats have demonstrated that approximately 80% of the dose is excreted in the bile and suggest that in man, biliary excretion is probably the principal route for fecal elimination.
Elderly: The pharmacokinetics of quinupristin and dalfopristin were studied in a population of elderly individuals (range 69 to 74 years). The pharmacokinetics of the drug products were not modified in these subjects.
Gender: The pharmacokinetics of quinupristin and dalfopristin are not modified by gender.
Renal Insufficiency: In patients with creatinine clearance 6 to 28 mL/min, the AUC of quinupristin and dalfopristin in combination with their major metabolites increased about 40% and 30%, respectively.
In patients undergoing Continuous Ambulatory Peritoneal Dialysis, dialysis clearance for quinupristin, dalfopristin and their metabolites is negligible. The plasma AUC of unchanged quinupristin and dalfopristin increased about 20% and 30%, respectively. The high molecular weight of both components of Synercid suggests that it is unlikely to be removed by hemodialysis.
Hepatic Insufficiency: In patients with hepatic dysfunction (Child-Pugh scores A and B), the terminal half-life of quinupristin and dalfopristin was not modified. However, the AUC of quinupristin and dalfopristin in combination with their major metabolites increased about 180% and 50%, respectively. (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.)
Obesity (body mass index ≥ 30): In obese patients the Cmax and AUC of quinupristin increased about 30% and those of dalfopristin about 40%.
Pediatric Patients: The pharmacokinetics of Synercid in patients less than 16 years of age have not been studied.
The streptogramin components of Synercid, quinupristin and dalfopristin, are present in a ratio of 30 parts quinupristin to 70 parts dalfopristin. These two components act synergistically so that Synercid's microbiologic in vitro activity is greater than that of the components individually.
Quinupristin's and dalfopristin's metabolites also contribute to the antimicrobial activity of Synercid. Iin vitro synergism of the major metabolites with the complementary parent compound has been demonstrated.
Mechanism of Action
The site of action of quinupristin and dalfopristin is the bacterial ribosome. Dalfopristin has been shown to inhibit the early phase of protein synthesis while quinupristin inhibits the late phase of protein synthesis. Synercid is bactericidal against isolates of methicillin-susceptible and methicillin-resistant staphylococci. The mode of action of Synercid differs from that of other classes of antibacterial agents such as β-lactams, aminoglycosides, glycopeptides, quinolones, macrolides, lincosamides and tetracyclines. Therefore, there is no cross resistance between Synercid and these agents when tested by the minimum inhibitory concentration (MIC) method.
Mechanism of Resistance
Resistance to Synercid is associated with resistance to both components (i.e., quinupristin and dalfopristin). In non-comparative studies, emerging resistance to Synercid has occurred.
Interaction with other Antibacterials
Iin vitro combination testing of Synercid with aztreonam, cefotaxime, ciprofloxacin, and gentamicin against Enterobacteriaceae and Pseudomonas aeruginosa did not show antagonism.
Iin vitro combination testing of Synercid with prototype drugs of the following classes: aminoglycosides (gentamicin),β-lactams (cefepime, ampicillin, and amoxicillin), glycopeptides (vancomycin), quinolones (ciprofloxacin), tetracyclines (doxycycline) and also chloramphenicol against enterococci and staphylococci did not show antagonism.
Staphylococcus aureus (methicillin-susceptible
The following in vitro data are available, but their clinical significance is unknown.
The combination of quinupristin and dalfopristin (Synercid) exhibits in vitro minimum inhibitory concentrations (MIC's) of ≤ 1.0 μg/mL against most ( ≥ 90%) isolates of the following microorganisms; however, the safety and effectiveness of Synercid in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
Staphylococcus aureus (methicillin-resistant isolates)
Staphylococcus epidermidis (including methicillin-resistant isolates)
Susceptibility Test Methods
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution1 method (broth or agar) or equivalent using standardized inoculum concentrations, and standardized concentrations of quinupristin/dalfopristin (Synercid) in a 30:70 ratio made from powder of known potency. The MIC values are interpreted according to the following criteria:
For Susceptibility Testing of Staphylococcus aureus,
and Streptococcus pyogenes (excluding Streptococcus pneumoniae)a.
|≤ 1.0||Susceptible (S)|
|≥ 4.0||Resistant (R)|
aThe interpretive values for Streptococcus pyogenes are applicable only to broth microdilution susceptibility testing using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.
A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the concentration of the antimicrobial compound in the blood reaches usually achievable levels. A report of “Intermediate” indicates that the result should be considered equivocal, and if the bacterium is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
A standardized susceptibility test procedure requires the use of laboratory control bacteria to control the technical aspects of the laboratory procedures. Standard quinupristin/dalfopristin powder in a 30:70 ratio should provide the following MIC values with the indicated quality control strains:
|Microorganisms (ATCC ® #)||MIC (μg/mL)|
|Staphylococcus aureus (29213)||0.25 to 1.0|
|Streptococcus pneumoniae (49619)1 a||0.25 to 1.0|
|1 The interpretive values for Streptococcus
pyogenes are applicable only to tests performed using Mueller-Hinton agar
supplemented with 5% sheep blood when incubated in 5% CO2.
a Streptococcus pneumoniae is used when testing Streptococcus pyogenes.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure1 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 μg quinupristin/dalfopristin in a ratio of 30:70 (Synercid) to test the susceptibility of bacteria to quinupristin/dalfopristin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15 μg quinupristin/dalfopristin disk are interpreted according to the following criteria:
For Susceptibility Testing of Staphylococcus aureus,
and Streptococcus pyogenes (excluding Streptococcus pneumoniae)b.
|Zone Diameter (mm)||Interpretation|
|≥ 19||Susceptible (S)|
|16 to 18||Intermediate (I)|
|≤ 15||Resistant (R)|
bThe zone diameter for Streptococcus pyogenes are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood when incubated in 5% CO2.
Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for quinupristin/dalfopristin.
As with standardized dilution techniques, diffusion methods require the use of laboratory control bacteria that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 15 μg quinupristin/dalfopristin (30:70 ratio) disk should provide the following zone diameter with the indicated quality control strain.
|Microorganism (ATCC® #)||Zone Diameter Range (mm)|
|Staphylococcus aureus (25923)||21 to 28|
|Streptococcus pneumoniae (49619)1 a||19 to 24|
|1 The zone diameter for Streptococcus pyogenes are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood when incubated in 5% CO2.
a Streptococcus pneumoniae is used when testing Streptococcus pyogenes.
Complicated Skin and Skin Structure Infections
Two randomized, open-label, controlled clinical trials of Synercid (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 Synercid; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 Synercid; n = 222 Comparator).
In the first study, 105 patients (45.9%) and 106 patients (48.0%) in the Synercid and Comparator arms, respectively, were found to be clinically evaluable. For the second study, these values were 113 (51.1%) and 120 (54.1%) patients in the Synercid and Comparator arms, respectively. Patients were found not to be clinically evaluable for reasons such as: wrong diagnosis, lower extremity infection in patients with diabetes or peripheral vascular disease since these infections were assumed to include aerobic gram-negative and anaerobic organisms, no specimen for culture obtained, insufficient therapy, no test of cure assessment, etc.
For the patients found to be clinically evaluable, in Study JRV 304 the success rate was 49.5% in the Synercid arm and 51.9% in the Comparator arm. In Study JRV 305, the success rates were 66.4% and 64.2% in the Synercid and Comparator arms, respectively.
The following table shows the clinical success rate (combined results from two clinical trials) in the clinically evaluable population. Due to the small numbers of patients in the subsets, statistical conclusions could not be reached.
|Infection Type||Cured or Improved|
|Traumatic wound infection||33/55||(60.0)||33/55||(60.0)|
1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility testing. CLSI document M100-S22. CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA 19807, 2012.
Last reviewed on RxList: 3/19/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Synercid Information
Synercid - User Reviews
Synercid User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.